Please complete the CAPTCHA to continue
A concise factual answer block for searchers comparing this professional profile.
Patrick Nj Schnegelsberg is listed as CEO | Chairman of the Board of Directors at SynCardia Systems, LLC, based in Tucson, Arizona, United States. AeroLeads shows a matched LinkedIn profile for Patrick Nj Schnegelsberg.
Patrick Nj Schnegelsberg previously worked as Chief Executive Officer at Syncardia Systems, Llc and Managing Partner at The Venture Office. Patrick Nj Schnegelsberg holds Medical Sciences, Medicine from Harvard Medical School.
This section adds company-level context without repeating Patrick Nj Schnegelsberg's masked contact details.
Review company-level records connected to Patrick Nj Schnegelsberg before choosing the right outreach path.
As CEO of SynCardia Systems, LLC, my focus on innovative MedTech solutions empowers our mission to enhance patient outcomes for those with critical heart conditions. Leading both strategic and operational facets, I leverage my expertise in pharmaceuticals, new business development, and business management to advance SynCardia's footprint in the medical device sector.Having assumed leadership roles that include Chairman at Acorai, my drive is to lower mortality rates and improve quality of life. My tenure reflects a commitment to fostering advancements in life sciences and delivering strategic guidance to optimize healthcare technologies and patient care.
Listed skills include Strategy, Biotechnology, Medical Devices, Pharmaceutical Industry, and 46 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Tucson, AZ, US
SynCardia Systems, LLC (www.syncardia.com) in Tucson, AZ., is the privately-held manufacturer of the world's first and only FDA and Health Canada approved Total Artificial Heart. Intended for patients suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia Total Artificial Heart (STAH) is used as a.
The Venture Office is an independent organization focused on providing clients with strategic and transactional advice in life science.
Helsingborg, SE
Acorai develops medical devices for non-invasive monitoring of intracardiac pressure with the aim to reduce re-hospitalizations due to heart failure, to lower mortality rates, and to improve patient's performance and quality of life.
Lund, SE
Syntach AB is innovation-driven company based in Lund, Sweden. The Company develops an entirely new class of minimally invasive cardiac support devices and other products aimed and improving the lives of millions of patients living with advanced stage heart failure.
Västerås, Västmanland, SE
Scandinavian Real Heart AB is developing an artificial heart (total artificial heart, TAH) that mimics the body's natural circulation and can be used in patients waiting for a heart transplant. The Company's TAH design and performance is expected to provide patients with increased mobility and a better quality of life.
Helsingborg, Helsingborg, SE
Occlutech Holding AG is a leading developer and manufacturer of proprietary, transcatheter devices for the repair of structural heart defects, the prevention of stroke, and treatment of heart failure symptoms. The Company markets and sells its products to hospitals and clinics in approximately 85 countries through its direct sales organization and via an.
Helsingborg, Helsingborg, SE
Occlutech Ltd., a wholly owned subsidiary of Occlutech Holding AG, develops and manufactures proprietary products for pediatric and adult interventional cardiology uses, including the Atrial Flow Regulator (AFR) for patients with left or right heart failure. For more information, please visit www.occlutech.com.Key achievements included: Restructuring and.
Procora was created to manage the global clinical and commercial development of the Atrial Flow Regulator (AFR), an innovative cardiac implant designed for use in patients with left or right heart failure. Key achievements included: building a start-up to develop the AFR device, successfully obtaining two Breakthrough Device Designations for the AFR.
NOLabs AB was a privately held MedTech company engaged in the development and commercialization of NitroSense technology for the administration and controlled release of nitric oxide gas. Key achievements: Re-aligned business from a focus on pain management to wound care, lead and managed the sale of NOLabs assets to an international wound-care company.
Frankfurt Am Main, Hessen, DE
M&A and investment banking advisory services for companies in the Life Sciences Sector.Key achievements included: securing over half a dozen advisory mandates including NOLabs, managed the sale of >$7MM neurostimulation assets to Cyberonics (LivaNova).
IL
GammaCan was a U.S.-Israeli, small-cap biotechnology company engaged in the clinical development of cancer immunotherapy for the treatment of melanoma. The Company was sold in 2008.Key achievements included: Raising $6.4MM and obtaining Orphan Drug Status.
New York-based investment advisory firm focused on global life science and healthcare sectors.Key achievements included: Expanding the bank’s reach into the Israeli biotech market and leading M&A for small-cap biotechs in Australia, and Europe.
New York, NY, US
New York-based investment bank focused on financing public companies in the global life science and healthcare sectors.Key achievements included: Raising over $50MM for small-cap biotech in PIPES, secondaries & reverse mergers.
Vadodara, Gujarat, IN
New York-based investment advisory firm and hedge fund focused on global life science and healthcare sectors.Key achievements included: 48.9% return on portfolio companies.
New York, NY, US
Global Management Consulting firm.Key achievements included: Lead role in formulating discovery strategy to monetize human genome for major Genomics company, the lead role in sale and execution of brain cancer therapy development strategy for leading U.S. clinic, and lead role in creating Best Practice / Industry Benchmarking documents on R&D Productivity.
Boston, MA, US
Consulting firm specialized in licensing and acquisition, due diligence, IP portfolio construction, business opportunity assessment, product clearance (FTO), and patent litigation.Key achievements include: Leading the firm’s expansion into the Biotech & Medical Devices sectors and selling projects worth over $5MM.
Quick answers generated from the profile data available on this page.
Patrick Nj Schnegelsberg works for SynCardia Systems, LLC.
Patrick Nj Schnegelsberg is listed as CEO | Chairman of the Board of Directors at SynCardia Systems, LLC.
Patrick Nj Schnegelsberg is based in Tucson, Arizona, United States while working with SynCardia Systems, LLC.
Patrick Nj Schnegelsberg has worked for Syncardia Systems, Llc, The Venture Office, Acorai, Syntach Ab, and Scandinavian Real Heart.
You can use AeroLeads to view verified contact signals for Patrick Nj Schnegelsberg at SynCardia Systems, LLC, including work email, phone, and LinkedIn data when available.
Patrick Nj Schnegelsberg holds Medical Sciences, Medicine from Harvard Medical School.
Patrick Nj Schnegelsberg is listed with skills including Strategy, Biotechnology, Medical Devices, Pharmaceutical Industry, Business Strategy, Life Sciences, Venture Capital, and Start Ups.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts